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Abstract 
Astrocytes constitute a very abundant cell type in the mammalian central nervous 
system, and play critical roles in brain function. During development, astrocytes are 
generated from neural progenitor cells only after these cells have generated neurons. 
This so called gliogenic switch is tightly regulated by intrinsic factors that inhibit the 
generation of astrocytes during the neurogenic period. Once neural progenitors acquire 
gliogenic competence, they differentiate into astrocytes in response to specific 
extracellular signals. Some of these signals are delivered by neurotrophic cytokines via 
activation of the gp130-JAK-STAT system, whereas others depend on the activity of 
pituitary adenylate cyclase-activating polypeptide (PACAP) on specific PAC1 receptors 
that stimulate the production of cAMP. This results in the activation of the small 
GTPases Rap1 and Ras, and in the cAMP-dependent entry of extracellular calcium into 
the cell. Calcium, in turn, stimulates the transcription factor DREAM, which is bound to 
specific sites of the promoter of the glial fibrillary acidic protein gene, stimulating its 
expression during astrocyte differentiation. Lack of DREAM in vivo results in 
alterations in the number of neurons and astrocytes generated during development. 
Thus, the PACAP-cAMP-Ca2+-DREAM signaling cascade constitutes an important 
pathway to activate glial-specific gene expression during astrocyte differentiation. 
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Introduction 
 Among glial cells, astrocytes constitute the most abundant cell type in the 
central nervous system (Bass et al., 1971; Nedergaard et al., 2003). In recent years a 
large body of data has accumulated in favor of the notion that these glial cells 
participate actively in the physiological processes of the brain by establishing a 
reciprocal relationship with neurons (Barres, 2008; Theodosis et al., 2008). This 
relationship is not only important to ensure selectively the availability of nutrients 
through the blood brain barrier, but also for the performance of important tasks that are 
essential for the correct function and survival of neurons. Thus, astrocytes are active 
participants in synaptic transmission and regulate intercellular communication processes 
(Haydon and Carmignoto, 2006; Perea and Araque, 2007), they prevent neurotoxicity 
from excitatory neurotransmitters and other compounds (Ashner et al., 1999; Maragakis 
and Rothstein, 2004), and they produce trophic factors that are essential for neuronal 
differentiation and survival (Gash et al., 1998; Blondel et al., 2000). Interestingly, in 
some brain areas astrocytes themselves can give rise to neurons (Seri et al., 2001). In 
addition, astrocytes appear to be an important element in the development of certain 
diseases (Araque, 2006; Chen et al., 2007; Lepore et al., 2008), and mutations in the 
gene encoding glial fibrillary acidic protein (GFAP), an intermediate filament protein 
characteristic of these cells, are associated with Alexander’s disease, a rare but 
devastating disorder of the central nervous system (Quinlan et al., 2007). 
 
Generation of astrocytes during brain development 
 The mechanisms by which astrocytes originate from neural precursors during 
embryonic development have received much attention in recent years. It is now well 
established that during gestation the generation of astrocytes occurs at a relatively late 
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stage, only after the generation of neurons has been practically completed, and proceeds 
postnatally. In rodents, neurogenesis spans approximately from embryonic day 12 (E12) 
to E18, whereas astrocytogenesis starts at around E17 and peaks a few days after birth. 
Importantly, both neurons and astrocytes arise in the developing neuroepithelium from 
the same progenitor cells, which appear to coincide with radial glial cells (Pinto and 
Gotz, 2007). Therefore, at a specific time during development progenitor cells are 
instructed to finish with the generation of neurons and to acquire a capacity to generate 
astrocytes. 
 This cellular switch from neurogenesis to gliogenesis is tightly regulated at 
different levels. One level of regulation involves the active inhibition of gliogenesis 
during the neurogenic period, so that precursors are unable to generate astrocytes even 
in the presence of astrogliogenic signals. One effective mechanism of inhibition consists 
on the methylation of astrocyte-specific genes leading to their inactivation in early 
progenitor cells (Takizawa et al., 2001; Namihira et al., 2004; Fan et al., 2005). In 
addition, inhibition of glia-specific genes in neuronal progenitors involves epigenetic 
silencing by chromatin remodeling (Song and Ghosh, 2004), as well as transcriptional 
repression (Hermanson et al., 2002; Angelastro et al., 2005). Interestingly, it has been 
found that transcription factors of the basic-helix-loop-helix family that promote the 
generation of neurons from progenitor cells, actively inhibit the expression of glial-
specific genes, thus preventing gliogenesis (Cai et al., 2000; Nieto et al., 2001; Sun et 
al., 2001). 
 Neural progenitors gain competence to generate astrocytes due to the activity of 
growth factors such as basic fibroblast growth factor and epidermal growth factor (Qian 
et al., 1997; Viti et al., 2003; Song and Ghosh, 2004). This gain of competence allows 
them to respond to specific gliogenic signals acting at the extracellular level. 
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Particularly important in this regard are signals provided by neurotrophic cytokines such 
as ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and 
cardiotrophin-1 (CT-1) (Johe et al., 1996; Bonni et al., 1997; Rajan and McKay, 1998; 
Barnabé-Heider et al., 2005). All of these cytokines activate heterodimeric cell surface 
receptors composed of two subunits named LIFRβ and gp130, which in turn activate 
members of the JAK family of tyrosine kinases, that result in the phosphorylation and 
nuclear translocation of signal transducer and activator of transcription (STAT) proteins 
(Schindler et al., 2007). In neural progenitors, two of these proteins, STAT1 and STAT3 
act on specific sites in the promoters of the astroglial genes GFAP and S100β to 
stimulate their transcription during the astrocyte differentiation process. In vivo studies 
carried out using genetically modified mice indicate that the gp130-JAK-STAT system 
is required for the generation of astrocytes, and that CT-1 provides a key regulatory 
signal for the activation of this system at the onset of the astrogliogenic period (Bugga 
et al., 1998; Koblar et al., 1998; Nakashima et al., 1999b; Barnabé-Heider et al., 2005). 
 Neural progenitors also respond to different neurotrophic factors from the bone 
morphogenetic proteins (BMP) family to generate astrocytes. In this case, BMP2 or 
BMP4 act on heterotrimeric receptors, which activate Smad transcription factors. These 
in turn, interact with activated STAT proteins to synergistically stimulate transcription 
of glial specific genes during astrocyte differentiation (Gross et al., 1996; Mehler et al., 
1997; Mabie et al., 1999; Nakashima et al., 1999a). 
 
Identification of PACAP as a cAMP-dependent signal for the generation of 
astrocytes 
 Apart from signals generated by diffusible factors acting on kinase-dependent 
receptors as discussed above, recent studies indicate that seven transmembrane domain 
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G-protein-coupled receptors activated by pituitary adenylate cyclase-activating 
polypeptide (PACAP) can trigger the differentiation of astrocytes via a mechanism that 
requires the production of intracellular cAMP (McManus et al., 1999; Vallejo and 
Vallejo, 2002; Cebolla et al., 2008). 
 The studies that led to the identification of PACAP as a neurotrophic factor 
capable of triggering the differentiation of astrocytes from cortical precursors were 
initiated with the observation that stimulation of the cAMP-dependent signaling 
pathway in primary cultures of neuroepithelial progenitors obtained from rat fetal cortex 
results in the differentiation of astrocytes after exit from the cell cycle (McManus et al., 
1999). This response observed after stimulation of the cAMP-dependent pathway in 
cortical progenitors is specifically instructive, because stimulation of this second 
messenger pathway does not result in the differentiation of neurons or oligodendrocytes 
(McManus et al., 1999), although these cells retain the capacity to differentiate into 
neurons in response to an appropriate stimulus such as BDNF (Lastres-Becker et al., 
2008). After this initial observation, a search for an extracellular ligand that could 
mimic the effect of cAMP was initiated. 
 As a putative role for monoamine neurotransmitters had been suggested in the 
developing brain (Levitt et al., 1997; Cameron et al., 1998), and these neurotransmitters 
act by binding to G-protein-coupled receptors that can activate the synthesis of cAMP, 
they became obvious candidates for the observed cAMP-dependent astrocytogenic 
response. Indeed, exposure of primary fetal cortical progenitors to monoamines results 
in phosphorylation of CREB, indicating that these cells express appropriate functional 
receptors. However, these experiments showed that these cells do not differentiate into 
astrocytes when exposed to dopamine, noradrenaline or serotonine, as assessed by 
changes in morphology and expression of GFAP (Vallejo and Vallejo, 2002).  
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 Having ruled out monoamines, it was considered that certain neuropeptides 
acting on specific G-protein-coupled receptors could trigger the differentiation of 
astrocytes from cortical precursors. Because of the known activity of PACAP to 
stimulate adenylate cyclase in neural cells, this peptide and the closely related 
vasoactive intestinal polypeptide (VIP) were tested to investigate whether they are able 
to induce astrocyte differentiation. 
 Both PACAP and VIP can bind with similar affinities to two specific receptors 
known as VPAC1 and VPAC2. In addition, PACAP recognizes a third receptor known 
as PAC1, for which VIP exhibits a comparatively low affinity (Harmar et al., 1998). All 
of these receptors stimulate adenylate cyclase activity, although PAC1 receptors can 
also stimulate phospholipase C, and both peptides have been reported to increase 
intracellular levels of cAMP in a variety of different cell types. 
 Experiments carried out with primary cultures of rat cortical progenitor cells 
demonstrated that PACAP, but not VIP, is able to promote their differentiation into 
astrocytes (Vallejo and Vallejo, 2002). The observed lack of effect of VIP and the 
specificity of PACAP is due to the circumstance that cortical neural progenitors express 
relatively high levels of the PAC1 receptor, but not VPAC1 or VPAC2 receptors. 
However, different isoforms of the PAC1 receptor generated by alternative splicing 
exist, and each one of these isoforms uses different signal transduction mechanisms. 
This is due to different configurations that may be adopted by the third intracellular 
loop of the receptor, which contains the domain that interacts directly with G-proteins to 
activate adenylate cyclase. Alternative splicing may result in the inclusion in this 
intracellular loop of one or two small cassettes called Hip and Hop, encoded by two 
different exons. This favors coupling of the receptor to the polyphosphoinositide-
specific phospholipase C-dependent signaling pathway (Spengler et al., 1993; Nicot and 
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DiCicco-Bloom, 2001). In addition, another PAC1 receptor isoform is able to stimulate 
calcium entry directly through the activation of an L-type calcium channel (Chatterjee 
et al., 1996). Therefore, the observation that PACAP is able to specifically mimic the 
astrocytogenic response of forskolin or 8Br-cAMP in cortical progenitors does not 
necessarily mean that this neuropeptide is using a cAMP-dependent mechanism to 
produce this effect. 
 To clarify this issue, several lines of experimentation were undertaken. First, it 
was determined that the most abundant isoform of the PAC1 receptor expressed in rat 
cortical progenitor cells is the short isoform that couples to the G protein-adenylate 
cyclase system. Relatively small amounts of PAC1 receptor containing the Hop 
cassette, and even smaller amounts of the isoform containing the Hip cassette were also 
detected, but interestingly these disappeared upon receptor activation with PACAP or 
upon treatment of cells with the cAMP analog 8Br-cAMP at the expense of an increase 
in the expression of the short isoform of the receptor (Vallejo and Vallejo, 2002). Thus, 
the same stimulus that triggers the production of cAMP response also induces changes 
at the receptor level to maximize this response. 
 In a different set of experiments, it was determined that PACAP can stimulate 
the synthesis of cAMP in rat neural progenitor cells, whereas VIP is practically inactive. 
Importantly, astrocyte differentiation by PACAP can be inhibited by pretreatment with 
Rp-cAMPS, a specific antagonist of cAMP, indicating that the production of this second 
messenger is a critical step to initiate the differentiation response (Vallejo and Vallejo, 
2002). 
 Thus, together these experiments demonstrated that PACAP can specifically 
induce astrocyte differentiation of primary cortical progenitor cells by acting on the 
short isoform of PAC1 receptors to stimulate intracellular cAMP production. 
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Interestingly, only a relative short exposure of cells to PACAP (15-30 minutes) is 
required to trigger the astrocytogenic response, which can be evident even 5 days after 
peptide treatment by morphological changes and by the stimulation of GFAP 
expression. Thus, as it is the case with other neurotrophic factors inducing neuronal or 
glial differentiation (Gross et al., 1996; Williams et al., 1997; Park et al., 1999), PACAP 
appears to initiate the response by stimulating cAMP production, but then other 
intracellular mechanisms take over to promote differentiation. 
 Watanabe et al. (2006), following studies carried out by the same group (Ohno 
et al., 2005), confirmed that PACAP is indeed capable to induce astrocyte 
differentiation by acting on PAC1 receptors. However, they did not find evidence in 
favor of a role for cAMP in this response, but instead proposed an involvement of 
phospholipase C and protein kinase C. These authors used relatively early (E14.5) 
mouse neural progenitor cells, as opposed to the E17 neural progenitors prepared from 
rat fetuses used in the experiments described above. In addition, relatively low 
concentrations of PACAP were used, and the differentiation of astrocytes took up to 5 
days to be observed (Ohno et al., 2005; Watanabe et al., 2006). Interestingly, it has been 
found that activation of PAC1 receptors in mouse neural precursors can generate both 
intracellular cAMP accumulation and activation of phospholipase C-mediated signaling 
leading to an increase in intracellular calcium, although this latter response appears to 
be related to proliferation of glial precursors rather than to differentiation (Nishimoto et 
al., 2007). Thus, differences in the species and experimental conditions may reflect the 
complex mechanisms activated by PACAP in the developing brain.  
 Both PACAP and the PAC1 receptor have been described to be present in the 
brain throughout development and postnatally (Suh et al., 2001; Nishimoto et al., 2007; 
Watanabe et al., 2007). A role for PACAP in the regulation of astrogliogenesis has been 
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proposed based on studies carried out by different investigators (Zupan et al., 1998; 
Vallejo and Vallejo, 2002; Ohno et al., 2005; Cebolla and Vallejo, 2006; Watanabe et 
al., 2006; Nishimoto et al., 2007; Cebolla et al., 2008; Lastres-Becker et al., 2008). 
However, it is clear that the role of PACAP during development is complex, because at 
different times during development it exerts different actions. Thus, independently of its 
activity as an astrogliogenic signal, PACAP acts as a potent antimitotic factor on 
relatively early neural progenitors and favors neuronal differentiation, whereas on late 
progenitors it regulates the generation of oligodendrocytes (Lee et al., 2001; Nicot and 
DiCicco-Bloom, 2001; Suh et al., 2001; Carey et al., 2002; Cazillis et al., 2004). This 
variety of responses at different times during development indicates that PACAP is an 
important neurotrophic factor whose activity is tightly regulated at different levels, 
including the specific type of receptor isoform expressed by neural progenitors, the 
different signal transduction pathways used by these receptors, the possible interaction 
of these pathways with molecules of signaling pathways activated by other neurotrophic 
factors, the type of transcription factors activated that act on specific target genes, and 
possibly the degree of responsiveness of these genes which may depend on epigenetic 
modifications. In turn, each one of these aspects may vary in different cells throughout 
development, thus providing an explanation for the high degree of versatility with 
which PACAP exerts different functions depending on the developmental stage and the 
type of the target cells on which it acts.  
 
Intracellular cAMP-dependent signaling triggered by PACAP in cortical 
precursors 
 As the differentiation of astrocytes from progenitor cells is accompanied by 
stimulation of the expression of the gene encoding GFAP, monitoring the 
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transcriptional activity of the GFAP promoter driving a reporter gene such as luciferase 
provided a useful approach to investigate the intracellular signaling pathways activated 
by PACAP during astrocyte differentiation from neural progenitors.  
 Activation of protein kinase A (PKA) was initially considered to be an obvious 
mechanism by which PACAP could stimulate GFAP gene expression and trigger 
astrocyte differentiation. This notion was supported by three lines of evidence: First, the 
astrogliogenic effect of PACAP on cortical progenitors can be inhibited by the cAMP 
antagonist Rp-cAMPS; second, treatment of cortical progenitors with PACAP results in 
phosphorylation of CREB, a well known substrate for PKA; and third, PACAP-induced 
CREB phosphorylation can be inhibited by pretreatment with the PKA inhibitor H89 
(Lastres-Becker et al., 2008). However, it soon became clear that PKA is not involved, 
because H89 was not able to inhibit the stimulation of GFAP gene expression nor the 
differentiation of astrocytes induced by PACAP. Thus, although PACAP can activate 
PKA in cortical progenitors, this activation may be responsible for other effects such as 
inhibition of proliferation (Lelievre et al., 2002), but not for inducing the differentiation 
of these progenitors into astrocytes. 
 Besides PKA, cAMP can stimulate at least two additional intracellular signaling 
cascades by binding to guanine nucleotide exchange proteins such as Epac and 
CNrasGEF (Pham et al., 2000; Bos, 2003). In cortical progenitors, PACAP is able to 
stimulate both pathways (Lastres-Becker et al., 2008). In the first case, exposure of cells 
to PACAP results in the activation of Rap1, which acts as an effector for cAMP-
activated Epac. In the second case, PACAP treatment leads to stimulation of Ras, an 
effect that can be inhibited by the cAMP-specific antagonist Rp-cAMPS. The activation 
of Rap1 and Ras by PACAP is not restricted to neural progenitors, since it has been 
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observed in different types of neurons and astrocytes (Bouschet et al., 2003; Dasgupta et 
al., 2003; Romano et al., 2003; Obara et al., 2007). 
 The notion that stimulations of these pathways are involved in triggering 
astrocyte differentiation by PACAP is supported by the observations that Rap1N17 or 
RasN17, which act as dominant negative inhibitors of Rap1 and Ras, respectively 
(Vossler et al., 1997; Matallanas et al., 2003), are able to decrease the stimulation of the 
GFAP gene promoter elicited by PACAP in cortical precursor cells. That Ras is 
stimulated in a cAMP-dependent manner was demonstrated by the observation that 
PACAP is unable to activate Ras in the presence of Rp-cAMPS, and that GFAP 
promoter stimulation by the stable cAMP analog 8Br-cAMP is significantly reduced in 
the presence of the dominant negative inhibitor RasN17 (Lastres-Becker et al., 2008). 
 Interestingly, stimulation of either the Epac-Rap1 or the cAMP-Ras pathway in 
isolation by using the selective activator of Epac 8CPT-2-O-Me-cAMP (Enserink et al., 
2002), or by expressing RasV12, a constitutively active form of Ras, is not sufficient to 
stimulate GFAP gene expression. For this to occur, both signaling cascades need to be 
concomitantly stimulated, consistent with the observations that coexpression of both 
RapN17 and RasN17 completely inhibits GFAP promoter stimulation by PACAP, and 
that combined knock down of Ras and Rap1 isoforms by siRNA prevents expression of 
GFAP after stimulation of cortical progenitors with PACAP (Lastres-Becker et al., 
2008). 
 The data described above, obtained using primary cultures of cortical precursors 
in vitro are in agreement with those observed in vivo (Apicelli et al., 2003). These 
authors generated transgenic mice expressing a constitutively active form of Rap1 under 
the control of the GFAP promoter, so that its expression is restricted to astrocytes from 
a time coinciding with astrogliogenesis at around E16. In these mice, astrocyte 
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differentiation was not significantly altered, as the number of astrocytes generated was 
similar to that of control mice. 
 
Transcriptional stimulation of the GFAP promoter by PACAP-cAMP 
 Studies to identify transcriptional mechanisms that activate and restrict the 
expression of the GFAP gene to astrocytes have been carried out both in cultured cells 
and in transgenic mice (Barnett et al., 1995; Bonni et al., 1997; Kahn et al., 1997; Rajan 
and McKay, 1998; Stone et al., 1998; Krohn et al., 1999; Nakashima et al., 1999a; Sun 
et al., 2001; Rajan et al., 2003; Lee et al., 2006; Lee et al., 2008).  
 Among the different transcription factors identified to date that regulate GFAP 
gene expression, some members of the NFI family appear to play a prominent role 
(Cebolla and Vallejo, 2006; Deneen et al., 2006; Gopalan et al., 2006). The NFI 
transcription factors comprise a family composed of at least four members with 
important functions during development (Gronostajski, 2000). Studies carried out in the 
developing spinal cord indicate that one member of this family, NFIA, is necessary for 
the gliogenic switch by which neural precursors inhibit their capacity to differentiate 
into neurons and acquire an astroglial phenotype (Deneen et al., 2006). In addition, NFI 
genes are important for the promotion of astrocyte differentiation, and their deletion 
results in decreased levels of GFAP expression (Das Neves et al., 1999; Shu et al., 
2003; Steele-Perkins et al., 2005; Deneen et al., 2006). 
 In the brain of rat fetuses NFI occupies specific sites of the GFAP promoter in 
vivo, and therefore it is not surprising that the onset of expression of NFI in the 
developing cortex coincides with the onset of GFAP expression during astrogliogenesis 
at around E17 (Cebolla and Vallejo, 2006). In the absence of NFI binding to the GFAP 
gene, activation of the promoter by astrogliogenic factors such as PACAP or CNTF 
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remains functional but is significantly impaired. NFI has been found to regulate 
transcription by presetting the chromatin for accessibility to other transcription factors 
(Belikov et al., 2004; Hebbar and Archer, 2007). Therefore, it is possible that NFI could 
be important in neural cells for maintaining the GFAP promoter in a favorable condition 
for its activation during astrocyte differentiation via a similar mechanism. This remains 
an important question to be addressed in future studies. 
 The stimulation of GFAP gene transcription by PACAP or by cAMP agonists 
even in the absence of NFI binding, although reduced, clearly indicates the existence of 
promoter elements that bind specific transcription factors different from NFI, which are 
activated by cAMP at the beginning of the astrocyte differentiation process. Analyses of 
the rat GFAP promoter in primary cultures of cortical progenitors led to the 
characterization of two regulatory elements bound by transcription factor DREAM, and 
to the demonstration that DREAM is the effector protein that mediates the 
transcriptional stimulation triggered by PACAP and cAMP at the onset of 
astrogliogenesis (Cebolla et al., 2008).  
 In addition, both PACAP and CNTF facilitate astrocytogenesis cooperatively, so 
that when both factors are present together, cells are generated with longer and more 
elaborate processes than those exposed to only one of these factors. This synergism 
does not occur in the absence of NFI binding to the GFAP promoter, suggesting that 
NFI is also important for the integration of different signaling pathways at the 
transcriptional level (Cebolla and Vallejo, 2006). The mechanism by which this 
integration resulting in synergism occurs is not known, but it is possible that it involves 
interactions of NFI with both STAT proteins and DREAM. In the first case, such type 
of interactions have been described in other cell types (Mukhopadhyay et al., 2001), 
whereas in the second, the NFI and DREAM binding sites in the rat and mouse GFAP 
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promoter are located in such close proximity (nucleotides -79 to -67 and -62 to -59, 
respectively, relative to the transcription initiation site) that direct interactions are 
indeed likely (Fig. 1). An analysis of the promoter sequences of the GFAP gene from 
different species using the UCSC Genome Bioinformatics database 
(http://genome.ucsc.edu) shows that the NFI binding site is well conserved among 
different species including rat, mouse, dog, cow and human. The adjacent DREAM 
binding site is conserved in rat and mouse, but is divergent in other species. However, a 
conserved DREAM binding site is present in the human GFAP promoter approximately 
160 base pairs upstream from the NFI site. 
 
DREAM transactivates the GFAP promoter in response to a cAMP-dependent 
increase in intracellular calcium 
 DREAM (Downstream Regulatory Element Antagonist Modulator) was initially 
identified as a repressor protein bound to regulatory elements located downstream from 
the transcription initiation site of the prodynorphin and c-fos genes (Carrion et al., 1999; 
Ledo et al., 2000). In cortical progenitor cells, DREAM is bound to at least two sites in 
the GFAP promoter even before they are induced to differentiate by PACAP, and once 
GFAP expression is initiated and astrocytes are generated DREAM remains bound. 
Indeed, the integrity of these two sites, and therefore binding of DREAM to the GFAP 
gene appears to be essential for promoter activity (Cebolla et al., 2008). 
 That DREAM is essential for mediating PACAP-induced stimulation of GFAP 
expression and astrocyte differentiation was initially indicated by the observation that 
cortical progenitor cells derived from DREAM-deficient mice fail to differentiate into 
astrocytes in response to PACAP, although they can still generate astrocytes in response 
to CNTF, indicating that the PACAP-DREAM signaling pathway works independently 
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of the gp130-JAK-STAT signaling pathway used by neurotrophic cytokines (Cebolla et 
al., 2008).  
 DREAM can be stimulated by interacting with the transcription factor αCREM 
after phosphorylation of this factor by PKA following activation by cAMP, or by direct 
binding of calcium ions to specific domains (Carrion et al., 1999; Ledo et al., 2000). In 
concert with the previous observation that PKA activation is not involved in the 
generation of astrocytes induced by PACAP, cAMP-dependent interactions of αCREM 
and DREAM are not involved in stimulation of GFAP expression by PACAP. On the 
contrary, PACAP/cAMP-induced GFAP expression in cortical progenitors requires the 
integrity of calcium-binding domains in DREAM (Cebolla et al., 2008), adding calcium 
as an additional component of the signaling cascade that links PACAP activation of 
PAC1 receptors with GFAP promoter stimulation. 
 PACAP can increase intracellular concentrations of calcium by a variety of 
mechanisms (Przywara et al., 1996; Osipenko et al., 2000; Morita et al., 2002; Liu et al., 
2003; Payet et al., 2003; Nishimoto et al., 2007). In rat cortical progenitors, this rise in 
calcium is due to entry from the extracellular milieu. As observed in other cell types 
(Przywara et al., 1996; Osipenko et al., 2000), PACAP-induced entry of calcium into 
the cells is mediated by cAMP, because pretreatment with the cAMP antagonist Rp-
cAMPS completely blocks this response (Cebolla et al., 2008). 
 The mechanism by which DREAM transactivates the GFAP promoter in 
response to calcium is unknown, but it is likely that it involves changes in protein 
conformation (Carrion et al., 1999; Osawa et al., 2001; Osawa et al., 2005). DREAM 
binds to DNA as a tetramer and ion-induced conformational changes result in the 
generation of calcium-bound DREAM dimers that normally do not bind DNA (Osawa 
et al., 2001; Osawa et al., 2005; Lusin et al., 2008). However, southwestern analysis has 
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shown that DREAM dimers can bind DNA (Carrion et al., 1999), and in the case of the 
GFAP promoter, this binding could be stabilized by interactions with other proteins 
bound in close proximity. In this regard, it is important to note that NFI occupies a site 
in the GFAP promoter located adjacent to one of the DREAM binding sites, and that 
binding of NFI to this site is important for GFAP expression during astrocyte 
differentiation (Cebolla and Vallejo, 2006). Thus, it is possible that DREAM is bound 
to the GFAP promoter as part of a multiprotein complex including NFI, and that 
calcium binding to DREAM induces conformational changes that favor positive 
interactions with coactivators or with other transcriptionally active proteins. Indeed, it 
has been indicated that the mechanism by which DREAM acts on target genes bearing 
DREAM binding sites upstream, rather than downstream of the TATA box, may be 
different and may involve interactions with other transcription factors (Rivas et al., 
2004; Gomez-Villafuertes et al., 2005; Scsucova et al., 2005).  
 In this regard, and in view of the observed capacity of DREAM to interact with 
other transcription factors (Ledo et al., 2000; Rivas et al., 2004; Scsucova et al., 2005), 
it is important to distinguish between the effects on GFAP promoter activation obtained 
experimentally after mutating either of the two DREAM binding sites in vitro, and the 
effects obtained on endogenous GFAP expression after inactivating the expression of 
DREAM in vivo. Thus, whereas the integrity of DREAM binding sites is essential for 
GFAP promoter activity in vitro, in cells lacking DREAM the GFAP promoter can still 
be functional (Cebolla et al., 2008). One possible interpretation of these apparently 
conflicting observations is that DREAM may be engaged in interactions with NFI 
and/or with other unidentified transcription factors assembled in such a way that 
promoter activity requires the coordinated binding of the complex, as depicted 
schematically in figure 1. Mutation of the DREAM binding sites could result in the 
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sequestration of the entire complex if DREAM is not given access to DNA (Fig. 1B). In 
contrast, in the absence of DREAM the remaining proteins could still be able to bind to 
their cognate sites on DNA and activate transcription (Fig. 1C). To validate or reject 
this model, studies to investigate whether DREAM interacts with NFI, or with STAT 
proteins or other transcription factors on the GFAP promoter in differentiating 
astrocytes will be required. 
 
DREAM and the timing of the transition from neurogenesis to gliogenesis 
 The physiological importance of DREAM in the mechanisms that regulate the 
generation of astrocytes during development was indicated by the observation that the 
number of astrocytes present during the early postnatal gliogenic period in mice lacking 
DREAM is reduced (Cebolla et al., 2008). This reduction is probably a reflection of a 
defect in the relay of PACAP/cAMP/calcium-dependent signals to the transcription 
machinery assembled on the GFAP gene, and is consistent with previous studies 
showing reduced number of astrocytes in the offspring of rats treated with a PACAP 
receptor antagonist during late pregnancy (Zupan et al., 1998). However, this reduction 
is not permanent. From the seventh day of postnatal life, the number of astrocytes in 
DREAM-mutant mice rises to even surpass that of control mice (Cebolla et al., 2008). 
Therefore, lack of DREAM does not affect other astrocyte-generating signals that may 
act coordinately during development. 
 The mechanisms that regulate the cellular switch by virtue of which cortical 
progenitors inhibit their capacity to generate neurons and start generating astrocytes are 
tightly linked. Therefore, when gliogenesis is inhibited a concomitant increase in 
neurogenesis may be observed. The reason for this is that signals that activate 
gliogenesis are also actively involved in the inhibition of neurogenesis (Miller and 
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Gauthier, 2007). It follows that if DREAM is also involved in repressing neurogenesis 
when astrogliogenesis is about to start, the initial decrease in the number of astrocytes in 
DREAM-deficient mice followed by the subsequent rise at a later stage could be 
interpreted as a delay in the onset of astrogliogenesis at the expense of maintaining 
neurogenesis for a longer period. Support for this interpretation is given by the 
observation that cortical progenitors of DREAM-mutant mice generate more neurons 
than those of control mice both in vitro and in vivo (Cebolla et al., 2008). But then, why 
are more astrocytes generated in the end? 
 The answer to this question may be related to the discovery that neurotrophic 
cytokines such as cardiotrophin-1 generated from neurons provide a powerful 
astrogliogenic signal (Barnabé-Heider et al., 2005). Thus, the proposed scenario would 
be that DREAM may have two different functions: on the one hand, it would inhibit 
neurogenesis at the end of the neurogenic period, and on the other hand, it would 
coordinately stimulate the generation of astrocytes from the same progenitor cells. This 
would explain that when DREAM is not present, neurogenesis would go on for a longer 
period of time generating an increased number of neurons at the expense of astrocytes. 
Later, neurotrophic cytokines secreted by these neurons would in turn act on the 
progenitors to inhibit neurogenesis and stimulate astrogliogenesis, and because of the 
initial overproduction of neurons these cytokines would be present in higher 
concentrations, thus resulting in a relative overproduction of astrocytes.  
 This model has two important implications. One is that lack of DREAM does 
not alter the gp130-JAK-STAT signaling pathway used by neurotrophic cytokines 
(Barnabé-Heider et al., 2005; Cebolla et al., 2008). The other is that during normal 
development, the astrogliogenic instructions delivered by the PACAP-cAMP-calcium-
DREAM system precede those delivered by neuron-generated neurotrophic cytokines. 
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Of course, future studies are needed to confirm or reject these notions. In addition, 
although lack of DREAM appears to affect astrocyte development throughout the brain 
(Cebolla et al., 2008), it remains to be determined whether in different regions of the 
developing central nervous system the stimulation of GFAP promoter by DREAM is 
activated by PACAP, as it appears to be the case with cortical astrocytes, or by different 
cAMP-generating factors acting on neural progenitor cells.  
 
Conclusions 
 Our understanding of the molecular mechanisms by which proliferating 
neuroepithelial progenitors differentiate into neurons and glial cells during brain 
development is increasing rapidly. The emerging scenario is one in which different 
types of processes acting at different levels, including epigenetic changes in chromatin, 
differential expression of transcription factors and specific interactions among them, as 
well as coordinated activation of intracellular signaling cascades triggered by factors 
acting on the cell membrane, are tightly regulated. The studies described in this review 
support the notion that the PACAP-cAMP-calcium-DREAM cascade constitutes an 
important signaling pathway that participates in the regulation of the gliogenic switch 
and the generation of astrocytes in the developing brain (Fig. 2). 
 Based on these studies emerging questions arise. For example, what is the 
mechanism by which NFI facilitates CNTF- and PACAP-induced GFAP expression? 
Does DREAM directly interact with NFI or STAT proteins? How does DREAM 
participate in the regulation of the number of neurons generated? Is DREAM involved 
in the stimulation of GFAP expression observed in reactive astrocytes? These questions 
open new avenues of investigations that will contribute to elucidate the complex 
mechanisms by which cellular diversity is generated in the mammalian brain. 
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FIGURE LEGENDS: 
Figure 1. Schematic depiction of a simplified model to illustrate a possible role 
DREAM in the regulation of GFAP gene transcription. A) In a normal situation, 
DREAM is bound to a site located in close proximity to the site bound by NFI, so that it 
is possible that DREAM and NFI interact. In addition, it is possible that DREAM and 
NFI interact with other unidentified transcription factors (UTF) that are required for 
transcriptional activity (arrow 1). DREAM mediates transcriptional responses to 
PACAP/cAMP (arrow 2), whereas STAT proteins, which bind to promoter elements 
located upstream, mediate transcriptional responses to neurotrophic cytokines such as 
CNTF or cardiotrophin-1 (arrow 3). In addition, NFI binding is required for the 
synergistic cooperation between CNTF and PACAP, which may involve transcriptional 
interactions (arrow 4). B) Sequestration of NFI and possibly other UTF by DREAM 
would explain that mutation of the binding sites for DREAM abolish basal and 
stimulated activity of the GFAP promoter. C) In DREAM deficient mice, PACAP-
dependent stimulation of GFAP transcription is inhibited, but the binding of other 
transcriptional transactivators remains unaltered (arrow 1) and gp130-JAK-STAT-
induced promoter activity is intact (arrow 3). In vivo, this results in delayed 
astrogliogenesis as a result of the absence of the PACAP-DREAM-dependent signal. D) 
When the NFI binding site is mutated, stimulation of the gp130-JAK-STAT and 
PACAP-DREAM signaling pathways are intact (arrows 2 and 3), but synergistic 
cooperation cannot occur (arrow 4) and overall promoter activity is decreased.  
 
Figure 2. Schematic depiction of the cAMP/calcium-dependent pathway activated by 
PACAP during astrocyte differentiation. PACAP acts on cortical precursors by 
activating seven transmembrane spanning domain PAC1 receptors. This results in the 
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stimulation of intracellular cAMP production by G-protein-mediated stimulation of 
adenylate cyclase (AC). Cyclic AMP activates PKA, Epac-Rap1 and Ras (probably by 
acting on CNrasGEF), but PKA does not contribute to stimulation of GFAP gene 
transcription during astrocyte differentiation. Exposure of precursor cells to PACAP 
results in calcium entry from the extracellular milieu, an effect that requires the activity 
of cAMP. Finally, calcium binds to DREAM, which occupies specific sites on the 
GFAP promoter, and following this GFAP gene transcription is stimulated. 
Independently of this pathway, GFAP transcription can also be stimulated by 
neurotrophic cytokines such as CNTF or cardiotrophin-1 (CT-1) via activation of the 
gp130-JAK-STAT pathway. Direct or indirect interactions between STAT proteins and 
DREAM, as described in Figure 1, could explain synergistic interactions of both 
pathways at the transcriptional level. 
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